Andreessen Horowitz January 8, 2021
Given its immense potential utility, AI is now a part of every link on bio’s value chain, from drug discovery, to diagnostic development, to healthcare delivery technologies. There are so many new applications for AI in bio — with more coming seemingly every day — that it is increasingly difficult to delineate the signal from the noise. A common question that we get from leaders in biopharma and healthcare, as well as investors and operators, is: “how do I assess a new AI-driven technology and make sure it is worth my time/effort/money?” This is an important question and in this piece, we will provide principles to abide by, point out some common pitfalls, and share how we think about evaluating...
Today's Sponsors
Today's Sponsor